Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 115

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 2
Chunk 115
---
 up to an aggregate
principal amount of $1,100,000 working capital loans. The sponsor further agrees that such loans shall be converted into Private
Placement Units, at the price of $10.00 per unit. To the extent the amount of such loans is less than $1,100,000, the sponsor
acknowledges and agrees that it (or, if applicable, it and any transferees of Private Placement Units) shall surrender for
cancellation any and all rights to up to an aggregate of 110,000 Private Placement Units at $10.00 per unit. As of September 30,
2025, there was $608,822 outstanding and reported as share subscription receivable on the unaudited balance sheet.

We
incurred $8,898,201 of transaction costs, consisting of $1,150,000 of cash underwriting fees, $6,900,000 of deferred underwriting fees,
and $848,201 of other offering costs.

We
intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust
account, which interest shall be net of taxes payable, if any, and excluding deferred underwriting commissions, to complete our initial
business combination. We may withdraw interest from the trust account to pay taxes, if any. To the extent that our share capital or debt
is used, in whole or in part, as consideration to complete an initial business combination, the remaining proceeds held in the trust
account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue
our growth strategies.

21

We
intend to use the funds from the Subscription Promissory Note primarily to identify and evaluate target businesses, perform business
due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses
or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate
and complete an initial business combination.

In
order to fund working capital deficiencies or finance transaction costs in connection with an initial business combination, our sponsor
or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required.
If we complete an initial business combination, we may repay such loaned amounts out of the proceeds of the trust account released to
us. In the event that a business combination does not close, we may use a portion